Clinical Trials Browser

Hodgkin Disease, Immunoblastic Lymphadenopathy, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT02232152 2023-08-07

CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

Phase 1 Completed

19 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT01835041 2023-07-12

CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

Phase 1 Completed

21 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05733000 2023-03-10

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Phase 2 Recruiting

94 enrolled

GastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT01766219 2019-05-15

CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery

Phase 1/2 Completed

17 enrolled 15 charts

Gastrointestinal

Bile Duct Neoplasms, Carcinoma, Hepatocellular

NCT01839981 2018-12-27

CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 1 Completed

10 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03370159 2018-08-01

CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer

Phase 1/2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01768897 2018-07-03

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Completed

67 enrolled

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT01931787 2018-07-03

CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Phase 1 Completed

15 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT01034475 2018-07-02

Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies

Phase 1 Completed

26 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02168907 2018-07-02

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1 Terminated

1 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Intraocular Lymphoma

NCT03435289 2018-02-19

A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer

Phase 1 Unknown

24 enrolled

Gastrointestinal

Pancreatic Neoplasms